Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone
(919) 668-1000
Email address
harry.erba@duke.edu
I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.
Education and Training
- Research Fellowship in Medicine, Medicine, Harvard Medical School, 1991 - 1993
- Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital, 1991 - 1992
- Clinical Fellow in Medicine, Medicine, Harvard Medical School, 1988 - 1991
- Residency Physician, Medicine, Brigham and Women's Hospital, 1988 - 1990
- Ph.D., Stanford University, 1988
- M.D., Stanford University, School of Medicine, 1988
Grants
- ALX Oncology: I/II of ALX148 in combo with Aza in patients with higher risk MDS
- Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
- ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naive Patients with Higher Risk Myelodysplastic Syndrome
- Agios MDS and Organ Impairment study
- A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
- Jazz 1b CPX-351 previously untreated AML
- NCI National Clinical Trials Network (UG1)
- Ph1b in patients with Hem Malignancies
- ImmunoGen_0802: Ph 1b/2 IMGN632
- Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias
- A PHASE 1 STUDY OF DS-3032B IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY, OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY
- A Phase I Study of DS-3201B in Subjects With Acute Myelogenous Leukemia (AML) Or Acute Lymphocytic Leukemia (ALL)
- A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- A phase 1, Multi-center, open-label study of IMGN632 administered intravenously in patients with relapsed/refractory CD123-positive acute myeloid leukemia and other CD123-positive hematologic mali
- Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Novartis Phase II MBG453 in combination with Venetoclax and Azacitidine in AML
- A Phase I/Ib, Multicenter, Open-Label, Dose-Escalation Study of FT-2102 as a Single agent and in Combination with Azacitidine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
- A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
- NCTN Network Group Operations Center
- A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD 123 X CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia